Pimecrolimus: A review

Journal of the European Academy of Dermatology and Venereology

Volumn 17, Issue 5, 2003, Pages 493-503

  Gupta, A K ^a,b   Chow, M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b Mediprobe Laboratories Inc   (Canada)

Author keywords

Pimecrolimus; SDZ ASM 981

Indexed keywords

ASCOMYCIN; AUTACOID; BETAMETHASONE VALERATE; CALCINEURIN; CLOBETASOL PROPIONATE; CYCLOSPORIN A; CYTOKINE; CYTOSOL RECEPTOR; IMMUNOMODULATING AGENT; IMMUNOPHILIN; LIGAND; NUCLEAR FACTOR; PHOSPHOPROTEIN PHOSPHATASE; PIMECROLIMUS; PLACEBO; TACROLIMUS;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CLINICAL OBSERVATION; CONTACT DERMATITIS; CREAM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; INHIBITION KINETICS; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PRURITUS; PSORIASIS; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SKIN ALLERGY; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN DISEASE; SKIN INFLAMMATION; SKIN IRRITATION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; ANIMALS; CHILD, PRESCHOOL; CONTROLLED CLINICAL TRIALS; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, ATOPIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PSORIASIS; SWINE; TACROLIMUS; TREATMENT OUTCOME;

EID: 0141650744     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.2003.00692.x     Document Type: Review

References (42)

1. Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Exp Opin Investig Drugs 2000; 9: 69-77.
2. Grassberger M, Baumruker T, Enz A et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin disease: in vitro pharmacology. Br J Dermatol 1999; 141: 263-273.
3. Luger T. Treatment of immune-mediated skin diseases: Future perspectives. Eur J Dermatol 2001; 11: 343-347.
4. Mrowietz U. Ascomycin macrolactams. J Cutan Med Surg 2001; 5: 22-25.
5. Paul C, Ho VC. Ascomycins in Dermatology. Semin Cutan Med Surg 1998; 17: 256-259.
6. Kehren J, Cordier A, Ebelin M-E et al. Genomic analysis of blood cells from psoriatic patients following treatment with oral pimecrolimus (SDZ ASM 981). The 10th Congress of the European Academy of Dermatology and Venereology (EADV) 2001; [Abstract].
7. Meingassner JG, Grassberger M, Fahrngruber H et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 568-576.
8. Meingassner JG, Fahrngruber H, Bavandi A. SDZ ASM 981 oral shows activity against murine allergic contact dermatitis, different from FK 506 and cyclosporin A. Am Acad Dermatol 2001; [Abstract].
9. Neckermann G, Bavandi A, Miengassner JG. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol 2000; 142: 669-679.
10. Van Leent EJM, Graeber M, Thurston M et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805-809.
11. Luger T, Van Leent EJM, Graeber M et al. SDZ ASM 981: an emerging safe and effective treatment of atopic dermatitis. Br J Dermatol 2001; 144: 788-794.
12. Kapp A, Bingham A, De Moor A et al. Pimecrolimus (SDZ ASM 981) cream 1%: A new approach to long-term management of atopic eczema in infants. The 10th Congress of the European Academy of Dermatology and Venereology (EADV) 2001; [Abstract].
13. Harper J, Lakhanpaul M, Wahn U et al. Pimecrolimus (SDZ ASM 981) blood levels are consistently low in children with extensive atopic eczema. The 10th Congress of the European Academy of Dermatology and Venereology (EADV) 2001; [Abstract].
14. Morris A, Cardno M, Burtin P et al. Low systemic SDZ ASM 981 exposure in children 5-16 years old treated with the 1% cream for their atopic dermatitis. J Eur Acad Dermatol Venereol 1999; 12 (Suppl. 2): S160. (In Paller AS. Use of nonsteroidal topical immunomodulators for the treatment of atopic dermatitis in the pediatric population. J Pediatr 2001; 138: 163-168.)
15. Harper J, Green A, Scott G et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001; 144: 781-787.
16. Greig G, Burtin P, Wolff K et al. Oral SDZ ASM 981: Clinical safety, tolerability, and efficacy in patients with moderate to severe chronic plaque psoriasis. Am Acad Dermatol 2001; [Abstract].
17. Rappersberger K, Komar M, Ebelin ME et al. Oral SDZ ASM 981: Safety, pharmacokinetics and efficacy in patients with moderate to severe chronic plaque psoriasis. J Invest Dermatol 2000; 144: 776.
18. Mrowietz U, Graeber M, Brautigam M et al. The novel ascomycin derivative SDZ ASM 981 is effective of psoriasis when used topically under occlusion. Br J Dermatol 1998; 139: 992-996.
19. Zonneveld IM, Rubins A, Jablonska S et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol 1998; 134: 1101-1102.
20. Mrowietz U, Wustlich S, Hoexter G et al. Pimecrolimus (SDZ ASM 981) ointment is effective in psoriasis without occlusion. The 10th Congress of the European Academy of Dermatology and Venereology (EADV) 2001; [Abstract].
21. Queille-Roussel C, Graeber M, Thurston M et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000; 42: 349-350.
22. Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks; a randomized, double-blind controlled study. Bri J Dermatol 2001; 144: 507-513.
23. Haapasaari KM, Risteli J, Karvonen J et al. Effect of hydrocortisone, methylprednisolone acetonate and mometasone furoate on collagen synthesis in human skin in vivo. Skin Pharmacol 1997; 10: 261-264.
24. Haapasaari KM, Risteli J, Koivukangas V et al. Comparison on the effect of hydrocortisone, hydrocortisone-17-butyrate and betamethason on collagen synthesis in human skin in vivo. Acta Derm Venereal 1995; 75: 269-271.
25. De Prost Y, Wahn U. Pimecrolimus (SDZ ASM 981) cream 1% reduces the need for topical corticosteroids to treat atopic eczema in children. The 10th Congress of the European Academy of Dermatology and Venereology (EADV) 2001; [Abstract].
26. Wahn U, Bos JD, Goodfield M et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110 (1pt1): e2.
27. Herbert AA, Warken KA, Cherill R. Pimecrolimus Cream 1%: A new development in nonsteroid topical treatment of inflammatory skin diseases. Semin Cutan Med Surg 2001; 20: 260-267.
28. Whalley D, McKenna S, Huels J et al. The benefit of pimecrolimus (SDZ ASM 981) on quality of life in the treatment of mild-to-moderate paediatric atopic eczema. The 10th Congress of the European Academy of Dermatology and Venereology (EADV) 2001; [Abstract].
29. Boguniewicz M, Eichenfield L, Honig P et al. Pimecrolimus (SDZ ASM 981) cream 1% is safe in the long-term management of atopic eczema. The 10th Congress of the European Academy of Dermatology and Venereology (EADV) 2001; [Abstract/Poster].
30. Wahn U, Pariser D, Gottlieb AB et al. Low blood concentrations of SDZ ASM 981 in infants with extensive atopic dermatitis treated with cream 1%. Am Acad Dermatol 2001; [Abstract/Poster].
31. Ho V, Halbert A, Takauka R et al. Pimecrolimus (SDZ ASM 981) cream 1% is effective and safe in infants aged 3-23 months with atopic dermatitis. The 10th Congress of the European Academy of Dermatology and Venereology (EADV) 2001; [Abstract].
32. Van Leent EJM, DeVries H, Scott G et al. Low blood concentrations of pimecrolimus (SDZ ASM 981) after topical treatment of adults with atopic eczema. The 10th Congress of the European Academy of Dermatology and Venereology (EADV) 2001; [Abstract].
33. Van Leent EJM, Ebelin ME, Burtin P et al. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesions. J Eur Acad Dermatol Venereol 1998; 11 (Suppl. 2): S133-134
34. Ruzicka T, Assmann T, Homey B. Tacrolimus: The drug for the turn of the millennium? Arch Dermatol 1999; 135: 574-580.
35. Lawrence ID. Tacrolimus (FK 506): Experience in dermatology. Dermatol Ther 1998; 5: 74-84.
36. Bieber T. Topical tacrolimus (FK 506): A new milestone in the management of atopic dermatitis. J Allergy Clin Immunol 1998; 102: 555-557.
37. Ho V. Treating the pathophysiological mechanisms of atopic dermatitis. Satellite Workshop: New Treatment Strategies - Atopic Dermatitis 2001; [Presentation].
38. Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981) - Preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20: 233-241.
39. Meingassner JG, Fahrngruber H, Bavandi A. SDZ ASM 981, in contrast to CyA and FK506, does not suppress the primary immune response in murine allergic contact dermatitis. J Invest Dermatol 2000; 114: 832.
40. Bochelen D, Rudin M, Sauter A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J Pharmacol Exp Ther 1999; 288: 653-659.
41. Meingassner JG, Di Padova F, Hiestand P et al. Pimecrolimus (SDZ ASM 981): Highly effective in models of skin inflammation by low activity in models of immunusuppression. The 10th Congress of the European Academy of Dermatology and Venereology (EADV) 2001; [Abstract].
42. Hanifin JM, Chan S. Biochemical and immunologic mechanism in atopic dermatitis: New targets for emerging therapies. J Am Acad Dermatol 1999; 41: 72-77.